Abstract
The ability to produce polysaccharides is widely found among microbial species. The structural diversity of the microbial polysaccharides (MPS) leads to a wide diversity of their applications. This review focuses pharmacological properties of MPS and their derivatives. They have been reported to possess many biological activities, such as antiviral, antitumor, antimicrobial and anticoagulant activities. So, the MPS of the type β-1,3-D-glucans, including curdlan and scleroglucan, show antitumor and antiviral activity. A number of biological and synthetic sulfated polysaccharides, including sulfated polysaccharides from marine microalgae, inhibit viral infections. Many of MPS demonstrate a series of attractive properties as carrier materials in drug delivery systems and nonviral gene delivery. Furthermore, MPS have found an application as wound-healing agents, blood plasma expanders and vaccines. Some MPS, like chitin, chitosan and alginate have an unusual combination of biological activities and physicochemical properties leading to the development of novel or improved pharmaceuticals. They have become of a great interest not only as drug and cell carriers but also as new functional materials of high biological activity, and recent progress in MPS chemistry is quite noteworthy. This review also examines the advances in the application of MPS in the field of tissue engineering.
Keywords: Microbial polysaccharides, antiviral activity, antitumor activity, antimicrobial activity, drug delivery systems, blood plasma expanders, vaccines, tissue engineering
Current Pharmaceutical Design
Title: Microbial Polysaccharides and their Derivatives as Current and Prospective Pharmaceuticals
Volume: 14 Issue: 29
Author(s): Andrija Smelcerovic, Zorica Knezevic-Jugovic and Zivomir Petronijevic
Affiliation:
Keywords: Microbial polysaccharides, antiviral activity, antitumor activity, antimicrobial activity, drug delivery systems, blood plasma expanders, vaccines, tissue engineering
Abstract: The ability to produce polysaccharides is widely found among microbial species. The structural diversity of the microbial polysaccharides (MPS) leads to a wide diversity of their applications. This review focuses pharmacological properties of MPS and their derivatives. They have been reported to possess many biological activities, such as antiviral, antitumor, antimicrobial and anticoagulant activities. So, the MPS of the type β-1,3-D-glucans, including curdlan and scleroglucan, show antitumor and antiviral activity. A number of biological and synthetic sulfated polysaccharides, including sulfated polysaccharides from marine microalgae, inhibit viral infections. Many of MPS demonstrate a series of attractive properties as carrier materials in drug delivery systems and nonviral gene delivery. Furthermore, MPS have found an application as wound-healing agents, blood plasma expanders and vaccines. Some MPS, like chitin, chitosan and alginate have an unusual combination of biological activities and physicochemical properties leading to the development of novel or improved pharmaceuticals. They have become of a great interest not only as drug and cell carriers but also as new functional materials of high biological activity, and recent progress in MPS chemistry is quite noteworthy. This review also examines the advances in the application of MPS in the field of tissue engineering.
Export Options
About this article
Cite this article as:
Smelcerovic Andrija, Knezevic-Jugovic Zorica and Petronijevic Zivomir, Microbial Polysaccharides and their Derivatives as Current and Prospective Pharmaceuticals, Current Pharmaceutical Design 2008; 14 (29) . https://dx.doi.org/10.2174/138161208786404254
DOI https://dx.doi.org/10.2174/138161208786404254 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Interrelationships with Metabolic Syndrome, Obesity and Cardiovascular Risk
Current Vascular Pharmacology Disulfiram: An Old Therapeutic with New Applications
CNS & Neurological Disorders - Drug Targets Phospholipase A2 Myotoxins from Bothrops Snake Venoms: Structure- Function Relationship
Current Organic Chemistry The Potential of Tetrandrine Against Gliomas
Anti-Cancer Agents in Medicinal Chemistry Progress in Syntheses of 3-n-Butylphthalide and Its Analogues
Current Organic Chemistry Small Molecules as Anti-TNF Drugs
Current Medicinal Chemistry Phosphodiesterase 5 Inhibitors - Drug Design and Differentiation Based on Selectivity, Pharmacokinetic and Efficacy Profiles
Current Pharmaceutical Design Molecular Properties Prediction and Synthesis of Novel Pyrazoline Carboxamide Analogs as Antitubercular Agents
Anti-Infective Agents Therapeutic Challenges in Neuroendocrine Tumors
Anti-Cancer Agents in Medicinal Chemistry Limited Hypotensive Effect of Sildenafil in a High-Risk Population: A Preliminary Report
Current Drug Safety Myocardial Infarction after Rituximab Treatment for Rheumatoid Arthritis: Is there a Link?
Current Pharmaceutical Design Blood Pressure Reduction in the Primary and Secondary Prevention of Stroke
Current Vascular Pharmacology Role of Vascular Nitric Oxide in Experimental Liver Cirrhosis
Current Vascular Pharmacology Mastering the Treatment of Diabetes Mellitus Type 1 in Childhood and Adolescence
Current Pediatric Reviews Hurdles in the Drug Discovery of Cathepsin K Inhibitors
Current Topics in Medicinal Chemistry Update on the Adverse Effects of Clozapine: Focus on Myocarditis
Current Drug Safety Polypharmacology of <i>Aconitum</i> and <i>Delphinium</i> sp. Diterpene Alka loids: Antiarrhythmic, Analgesic and Anti-Inflammatory Effects
Mini-Reviews in Organic Chemistry Medical Complications in Anorexia and Bulimia Nervosa
Endocrine, Metabolic & Immune Disorders - Drug Targets New Indications for Corticosteroids in Intensive Care Units
Current Drug Targets Sildenafil is Well Tolerated by Erectile Dysfunction Patients Taking Antihypertensive Medications, Including Those on Multidrug Regimens
Current Drug Safety